Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Inhibikase Therapeutics (IKT) Other Operating Expenses (2020 - 2025)

Inhibikase Therapeutics (IKT) has disclosed Other Operating Expenses for 3 consecutive years, with $642169.0 as the latest value for Q4 2025.

  • Quarterly Other Operating Expenses changed N/A to $642169.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$1.4 million through Dec 2025, changed N/A year-over-year, with the annual reading at -$1.4 million for FY2025, N/A changed from the prior year.
  • Other Operating Expenses for Q4 2025 was $642169.0 at Inhibikase Therapeutics, up from -$492827.0 in the prior quarter.
  • The five-year high for Other Operating Expenses was $642169.0 in Q4 2025, with the low at -$10.6 million in Q4 2023.